Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929565 · ClinicalTrials.gov registry record
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
A clinical trial, sponsored by University of Oklahoma.
- Completed
- Registry status
- 10
- Enrollment target
NCT00929565 is a clinical trial that has completed, run by University of Oklahoma. The registered enrollment target is 10 participants.
The verdict
NCT00929565 has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929565
The ClinicalTrials.gov registry entry for NCT00929565 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00929565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929565 about?
NCT00929565 is a clinical study titled "Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy". Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. ...
What is the current status of trial NCT00929565?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2009-06. Estimated completion is 2011-10.
Who is sponsoring clinical trial NCT00929565?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.